WHO ICTRP trial

Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel…

JPRN-UMIN000010055 · Japan Primary Registries Network (JPRN) · Recruiting

Key facts

Trial ID JPRN-UMIN000010055
Public title Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapy
Scientific title Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapy - Phase II study evaluating the efficacy and safety of…
Primary sponsor Respiratory Center, Showa University Northern Yokohama Hospital
Registry Japan Primary Registries Network (JPRN)
Recruitment status Recruiting
Study type Interventional
Phase Phase II
Countries Japan
Conditions advanced relapsed non-squamous NSCLC
Interventions If the disease is stable after four courses of CBDCA+PEM+BEV as induction therapy, patients will be treated with DTX+BEV as maintenance therapy until progression disease.
Registration date Feb 18, 2013
Target size 20
Registry page center6.umin.ac.jp

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations